Switching from Mounjaro to Wegovy: what actually changes

Why does the switch matter? Aren't they basically the same drug?

It is a fair question, and an understandable one. Mounjaro (tirzepatide) and Wegovy (semaglutide) are both injectable GLP-1 medicines used for weight management, and they share a family resemblance: once-weekly subcutaneous injection, broadly similar side-effect profiles, and a dose-escalation approach designed to give your body time to adjust. But the mechanism is genuinely different. Tirzepatide activates two receptors (GIP as well as GLP-1) which is why it is described as a dual agonist. Semaglutide activates GLP-1 receptors only. Whether that translates into a meaningful real-world difference for you specifically is something a prescriber is better placed to judge than a comparison article.

The clinical trial evidence does show a gap on average. In SURMOUNT-1, participants on tirzepatide 15mg lost around 20–21% of body weight over 72 weeks, as published in the New England Journal of Medicine. The SURMOUNT-5 head-to-head trial, also published in the NEJM in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over the same period. STEP 1 reported approximately 15% average reduction with semaglutide 2.4mg over 68 weeks. Averages, though, are not individual predictions. Some people respond strongly to semaglutide; others tolerate tirzepatide less well. If you are curious about the detailed differences in results and side effects, the Wegovy vs Mounjaro comparison goes deeper on the numbers.

What actually changes when you switch?

Several practical things shift the moment you move from tirzepatide to semaglutide, and it helps to know about them in advance so nothing catches you off guard.

The dose schedule restarts. You do not carry your Mounjaro dose across. Semaglutide has its own titration pathway, starting at 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and 2.4mg as the standard maintenance, each step roughly four weeks apart at the prescriber's discretion. A higher 7.2mg dose was approved by the MHRA in January 2026 and the single-dose 7.2mg pen received approval on 14 April 2026, as confirmed in the MHRA's announcement. Your prescriber will advise which starting point is appropriate for your circumstances; it is not something to decide alone.

The pen itself is different. Mounjaro comes as a KwikPen delivering four weekly doses from a single device. Wegovy uses pre-filled pens with a different mechanism. The injection sites are the same general areas (abdomen, thigh or upper arm, rotated) but the technique and the feel of the device differ. If needle-handling is something you have thought about, this page on whether Wegovy needles match Mounjaro's answers the specifics. Changing devices also means updating how you store and travel with your medication.

The side-effect pattern may shift. Both medicines share a GI-led profile (nausea, constipation, indigestion, and fatigue are common across both, especially after dose increases) but some people notice a difference in intensity or character when they switch. Because you are essentially restarting a titration, the early-dose adjustment period happens again. That is not a reason to avoid switching if it is clinically right for you; it is just worth knowing so you are not surprised. If you want a fuller picture of what happens when you switch from Mounjaro to Wegovy, including how the body typically responds during the transition, there is more detail on that dedicated page.

The cost picture changes. Tirzepatide and semaglutide are priced differently in the private market. For a grounded sense of how the numbers compare, this breakdown of the price difference between Mounjaro and Wegovy sets out what is typical.

How should a switch be managed clinically?

This is where patience is genuinely worth it. Switching between two prescription-only medicines without a clinical review is not safe practice, and a prescriber will want to understand a few things before recommending a change: how long you have been on Mounjaro, which dose you are currently taking, how well you have tolerated it, how much weight you have lost, and why you want to switch. Those details shape the plan.

It is also worth flagging that combining both medicines at the same time is not recommended. If you are curious about the risks involved, this page on taking both at once covers what is known. A prescriber will typically advise on a clean transition rather than any overlap.

Contraception is worth raising at the same time. For anyone using oral contraceptives, MHRA guidance notes that tirzepatide may reduce pill absorption, particularly in the first four weeks of treatment and after each dose increase. Semaglutide does not carry the same specific warning, according to NHS England's guidance on weight-management injections. A switch therefore changes the advice on back-up contraception, and a prescriber needs to know your contraceptive method before recommending a change.

Is the switch ever clinically recommended?

Yes, in certain situations. If someone is not tolerating tirzepatide well despite a slow titration, or if there is a clinical reason a prescriber prefers semaglutide, switching is a legitimate option. The reverse is also true: people may start on Wegovy and later move to Mounjaro. Neither direction is unusual, and neither is inherently better. Which medicine suits you is a clinical decision made with a prescriber who knows your full picture, not a conclusion a comparison table can reach. The table below sets out the key factual differences to support that conversation.

If you would like to talk through your situation with a prescriber, our team reviews consultations the same day. Speak to our prescribers and get a clear clinical picture rather than guesswork.